Precision Biosciences (DTIL) Short term Debt (2021 - 2024)

Precision Biosciences (DTIL) has 3 years of Short term Debt data on file, last reported at $22.5 million in Q2 2024.

• Quarterly Short term Debt rose 0.79% year-over-year to $22.5 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $22.5 million (up 0.79% YoY) and the FY2023 annual result came in at $22.4 million, changed N/A from the prior year.
• Short term Debt held at $22.5 million in Q2 2024 per DTIL's latest filing, from $22.5 million in the prior quarter.
• Across five years, Short term Debt topped out at $22.5 million in Q2 2024 and bottomed at $2.4 million in Q2 2021.
• The 3-year median for Short term Debt is $22.4 million (2023), against an average of $16.7 million.
• Peak annual rise in Short term Debt reached 0.79% in 2024, while the deepest fall reached 0.79% in 2024.
• Tracing DTIL's Short term Debt over 3 years: stood at $2.5 million in 2021, then surged by 813.28% to $22.4 million in 2023, then increased by 0.37% to $22.5 million in 2024.
• Per Business Quant, the three latest DTIL Short term Debt figures stand at $22.5 million (Q2 2024), $22.5 million (Q1 2024), and $22.4 million (Q4 2023).

Peer Comparison